Involvement of the Inositol-trisphosphate Receptor in Invasive or Migratory-type Breast Cancers
NCT03107234 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2017-04-11
Summary
Breast cancer is the leading cause of female cancer and female death by cancer in France. Despite the improvement in early detection and therapeutic arsenal, the mortality of this cancer remains high with 11 886 deaths estimated in 2012. Breast cancer is most often a carcinoma born from the lobular or ductal epithelium and is classified In two main categories: non invasive and invasive. Invasive breast cancers account for 75% of the cases. They are usually ductal (75%) and more rarely lobular (25%). The cancer cells are then no longer circumscribed to the galactophoric canals or glands but have invaded neighboring tissues. If they are not treated in time, these cancers can then spread: the cancerous cells will then migrate either by the lymphatic vessels to reach the neighboring ganglia or through the blood vessels to give metastases in other tissues In the liver, lungs and bones). The mortality associated with breast cancer is not due to the growth of the primary tumor but rather to the occurrence of metastases. The study of the mechanisms leading to metastatic invasion (i.e. migration and invasion) is therefore of considerable importance. The development of metastases depends on the acquisition by the cancer cells of various capacities including that of being able to migrate, involving a remodeling of the cytoskeleton highly dependent on the intracellular calcium (Ca2 +) concentration. Several types of signals are able to induce mobilization of Ca2 + from the extracellular medium or endoplasmic reticulum (ER) reserves. At the intracellular level, some of these signals are generated by inositol (1,4,5) -trisphosphate (IP3) from the activation of G protein-coupled receptors or certain receptors with tyrosine kinase activity. Has been shown that the expression, activity and regulation of IP3R receptors (IP3Rs) are involved in the cancerous processes of many tissues, in particular in the phenomena of proliferation of breast cancer cells. Overall, altered expression and / or activity of IP3Rs can be used for the survival, growth, proliferation and migration of cancer cells.
In the laboratory, the investigator showed that regulation of the expression of subtype 3 (IP3R3) by 17β-estradiol (E2) is involved in the growth of the human mammary cancer line MCF-7. E2 triggers the release of Ca2 + in an IP3-dependent mechanism, while prolonged exposure to E2 leads to an increase in the expression of IP3R3. At the same time, the reduction in the expression of IP3R3 cancels the proliferative effect of E2 on MCF-7 cells. More recently, the investigator has established that IP3R3 regulates the proliferation of cells of the human MCF-7 mammary cancer cell line via a molecular and functional interaction with the Ca2 + -dependent BKCa potassium channel. The determination of IP3Rs, including subtype 3, as a mediator / marker of breast carcinogenesis appears to be a major clinical issue.
Conditions
- Breast Cancer
- Inosine Triphosphatase
Interventions
- OTHER
-
Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
Sponsors & Collaborators
-
Centre Hospitalier Universitaire, Amiens
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-20
- Primary Completion
- 2018-07-17
- Completion
- 2018-07-17
Countries
- France
Study Locations
More Related Trials
-
Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET
NCT02850302 ·Status: COMPLETED ·Phase: NA
-
Definitive Radiation Therapy for Inoperable Breast Cancer
NCT07122713 ·Status: RECRUITING ·Phase: NA
-
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
NCT00084539 ·Status: COMPLETED ·Phase: PHASE2
-
RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer
NCT03000764 ·Status: COMPLETED ·Phase: NA
-
Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse
NCT03630653 ·Status: TERMINATED ·Phase: NA
-
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
NCT06358625 ·Status: RECRUITING
-
Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
NCT01434420 ·Status: UNKNOWN ·Phase: NA
-
Study of Metabolites Markers in Adjuvant Breast Cancer
NCT03367208 ·Status: COMPLETED
-
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
NCT01770353 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
NCT02833233 ·Status: COMPLETED ·Phase: NA
-
Predictive Clinical and Biological Parameters in Breast Cancer
NCT01521676 ·Status: TERMINATED ·Phase: NA
-
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
NCT05923177 ·Status: COMPLETED ·Phase: PHASE1
-
5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma
NCT02791750 ·Status: COMPLETED
-
SENOVIE France - Therapeutic Mobility and Breast Cancer
NCT06503393 ·Status: COMPLETED
-
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France
NCT03884413 ·Status: COMPLETED
-
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer
NCT01502592 ·Status: COMPLETED ·Phase: PHASE1
-
Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities
NCT00145197 ·Status: COMPLETED ·Phase: NA
-
Persistant Organics Pollutants in Breast Cancer.
NCT03788187 ·Status: COMPLETED ·Phase: NA
-
Follow-up in Early and Locally Advanced Breast Cancer Patients
NCT03859453 ·Status: COMPLETED
-
Reproductive Health in Breast Cancer Survivor
NCT06756802 ·Status: ACTIVE_NOT_RECRUITING
-
Patient Centered Randomized Controlled Trial
NCT00233077 ·Status: COMPLETED ·Phase: NA
-
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NCT04960839 ·Status: RECRUITING ·Phase: NA
-
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)
NCT04012229 ·Status: COMPLETED
-
Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer
NCT01051492 ·Status: UNKNOWN
-
Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01796041 ·Status: COMPLETED ·Phase: EARLY_PHASE1